AIMEE BROUSSARD: Open Payments
NPI 1710209044 · BROUSSARD, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,550 in 196 payments from 18 companies in 2025. Trend: 2023 $3,024 · 2024 $3,079 · 2025 $3,550
Food & beverage: $3,550
| Company | Payments | Amount |
|---|---|---|
| Axsome Therapeutics, Inc. | 20 | $438 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 24 | $396 |
| Otsuka America Pharmaceutical, Inc. | 20 | $374 |
| Janssen Pharmaceuticals, Inc | 11 | $328 |
| Alkermes, Inc. | 23 | $321 |
| ABBVIE INC. | 23 | $297 |
| Vanda Pharmaceuticals Inc. | 14 | $278 |
| Corium, LLC | 14 | $221 |
| Lundbeck LLC | 9 | $204 |
| Neurocrine BioSciences, Inc. | 9 | $148 |
Products named: REXULTI, Auvelity, CAPLYTA, ARISTADA, VRAYLAR, FANAPT, INVEGA SUSTENNA, Azstarys.
Industry payments across LA — which companies pay providers there.
